New anti-migraine drugs including gepants, lasmiditan, and CGRP monoclonal antibodies have distinct drug interaction profiles that clinicians must consider when prescribing.
8 new drugsAnti-migraine medications reviewed for drug-drug interactions, spanning three distinct drug classes
What the researchers found
Gepants and lasmiditan have significant drug interaction potential with CYP3A4 inhibitors, serotonergic drugs, and transporter inhibitors, while CGRP monoclonal antibodies have pharmacodynamic interactions related to immune modulation.
Why it matters
Migraine patients often take multiple medications. Understanding drug interactions prevents adverse effects and ensures these new treatments are used safely.
The numbers in context
7 drugs reviewed; gepants: CYP3A4/P-gp/BCRP; lasmiditan: serotonergic; mAbs: FcγR interactions
How the study worked
Review of published pharmacokinetic, pharmacodynamic, and drug interaction data for lasmiditan, gepants, and CGRP monoclonal antibodies.
Who was studied
Pharmacology review (no study population)
What this study cannot tell us
Review based on available data at time of publication. Long-term interaction data and real-world evidence still accumulating.
How to read the evidence
Review of pharmacological data from clinical trials and regulatory submissions. Reliable drug interaction information but real-world experience still growing.
When this study was published
Published in 2020. Additional interaction data have accumulated since then as these drugs are more widely used.
The bigger picture
As CGRP-targeting drugs become standard migraine therapy, clinicians need comprehensive drug interaction data to safely integrate them into patients' existing medication regimens.
Questions still open
- Are there clinically significant interactions between gepants and common co-prescribed medications?
- How do CGRP antibody interactions differ from traditional small molecule drug interactions?
- Should specific drug combinations be avoided with lasmiditan?
Common questions
Do new migraine drugs interact with other medications?
Are CGRP antibodies safer than gepants for drug interactions?
Read the original research
Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies.
Pharmaceutics, 12(12)
Citation
Szkutnik-Fiedler, Danuta. (2020). Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies.. Pharmaceutics, 12(12). https://doi.org/10.3390/pharmaceutics12121180